Clinical Trial Record

Return to Clinical Trials

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers


2013-10


2019-05-23


2019-05-23


200

Study Overview

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

This randomized clinical trial studies the Family Caregiver Palliative Care Intervention in supporting caregivers of patients with stage II-IV gastrointestinal, gynecologic, urologic and lung cancers. Education and telephone counseling may reduce stress and improve the well-being and quality of life of caregivers of cancer patients.

PRIMARY OBJECTIVES: I. Test the effects of the Family Caregiver Palliative Care Intervention (FCPCI) on family caregivers of patients with gastrointestinal, gynecologic, urologic and lung cancers in the experimental group on caregiver burden and caregiving skills preparedness as compared to family caregivers in the control group. II. Test the effects of the FCPCI on family caregivers of patients with gastrointestinal, gynecologic, urologic and lung cancers in the experimental group on quality of life (QOL) and psychological distress as compared to family caregivers in the control group. SECONDARY OBJECTIVES: I. Describe family caregivers' self-care behavior, comparing the experimental and control groups. II. Describe family caregivers' resource use, comparing the experimental and control groups. III. Identify subgroups of family caregivers who benefit most from the FCPCI in relation to sociodemographic, health status, and patient characteristics. IV. Describe family caregivers' satisfaction with the FCPCI. V. Describe caregiver out-of-pocket costs and the cost of the intervention. OUTLINE: Participants are randomized to 1 of 2 arms. ARM I: Participants receive FCPCI with an advanced practice nurse (APN), comprising 4 home education sessions once weekly followed by 4 telephone support sessions for 30 minutes once monthly and 24 hour telephone support available for 6 months. ARM II: Participants receive usual care

  • Healthy Subject
  • Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
  • Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
  • Psychosocial Effects of Cancer and Its Treatment
  • Recurrent Bladder Cancer
  • Recurrent Cervical Cancer
  • Recurrent Colon Cancer
  • Recurrent Gastric Cancer
  • Recurrent Ovarian Epithelial Cancer
  • Recurrent Ovarian Germ Cell Tumor
  • Recurrent Pancreatic Cancer
  • Recurrent Rectal Cancer
  • Recurrent Renal Cell Cancer
  • Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
  • Recurrent Urethral Cancer
  • Recurrent Uterine Sarcoma
  • Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
  • Stage II Bladder Cancer
  • Stage II Renal Cell Cancer
  • Stage II Urethral Cancer
  • Stage IIA Cervical Cancer
  • Stage IIA Colon Cancer
  • Stage IIA Gastric Cancer
  • Stage IIA Ovarian Epithelial Cancer
  • Stage IIA Ovarian Germ Cell Tumor
  • Stage IIA Pancreatic Cancer
  • Stage IIA Rectal Cancer
  • Stage IIA Uterine Sarcoma
  • Stage IIB Cervical Cancer
  • Stage IIB Colon Cancer
  • Stage IIB Gastric Cancer
  • Stage IIB Ovarian Epithelial Cancer
  • Stage IIB Ovarian Germ Cell Tumor
  • Stage IIB Pancreatic Cancer
  • Stage IIB Rectal Cancer
  • Stage IIB Uterine Sarcoma
  • Stage IIC Colon Cancer
  • Stage IIC Ovarian Epithelial Cancer
  • Stage IIC Ovarian Germ Cell Tumor
  • Stage IIC Rectal Cancer
  • Stage III Bladder Cancer
  • Stage III Pancreatic Cancer
  • Stage III Renal Cell Cancer
  • Stage III Urethral Cancer
  • Stage IIIA Cervical Cancer
  • Stage IIIA Colon Cancer
  • Stage IIIA Gastric Cancer
  • Stage IIIA Ovarian Epithelial Cancer
  • Stage IIIA Ovarian Germ Cell Tumor
  • Stage IIIA Rectal Cancer
  • Stage IIIA Uterine Sarcoma
  • Stage IIIB Cervical Cancer
  • Stage IIIB Colon Cancer
  • Stage IIIB Gastric Cancer
  • Stage IIIB Ovarian Epithelial Cancer
  • Stage IIIB Ovarian Germ Cell Tumor
  • Stage IIIB Rectal Cancer
  • Stage IIIB Uterine Sarcoma
  • Stage IIIC Colon Cancer
  • Stage IIIC Gastric Cancer
  • Stage IIIC Ovarian Epithelial Cancer
  • Stage IIIC Ovarian Germ Cell Tumor
  • Stage IIIC Rectal Cancer
  • Stage IIIC Uterine Sarcoma
  • Stage IV Bladder Cancer
  • Stage IV Gastric Cancer
  • Stage IV Ovarian Epithelial Cancer
  • Stage IV Ovarian Germ Cell Tumor
  • Stage IV Pancreatic Cancer
  • Stage IV Renal Cell Cancer
  • Stage IV Urethral Cancer
  • Stage IVA Cervical Cancer
  • Stage IVA Colon Cancer
  • Stage IVA Rectal Cancer
  • Stage IVA Uterine Sarcoma
  • Stage IVB Cervical Cancer
  • Stage IVB Colon Cancer
  • Stage IVB Rectal Cancer
  • Stage IVB Uterine Sarcoma
  • Ureter Cancer
  • Stage IIA Lung Carcinoma
  • Stage IIB Lung Carcinoma
  • Stage IIIA Lung Carcinoma
  • Stage IIIB Lung Carcinoma
  • OTHER: educational intervention
  • BEHAVIORAL: telephone-based intervention
  • PROCEDURE: quality-of-life assessment
  • OTHER: questionnaire administration
  • 08176
  • NCI-2013-00839 (REGISTRY Identifier) (REGISTRY: CTRP (Clinical Trial Reporting Program))

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2013-05-01  

N/A  

2020-01-21  

2013-05-01  

N/A  

2020-01-23  

2013-05-03  

N/A  

2020-01  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Supportive Care


Allocation:
Randomized


Interventional Model:
Parallel


Masking:
Single


Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Arm I (FCPCI)

Participants receive FCPCI with an APN, comprising 4 home education sessions once weekly followed by 4 telephone support sessions for 30 minutes once monthly and 24 hour telephone support available for 6 months.

OTHER: educational intervention

  • Receive FCPCI home education sessions

BEHAVIORAL: telephone-based intervention

  • Receive FCPCI telephone support sessions and 24 hour telephone support

PROCEDURE: quality-of-life assessment

  • Ancillary studies

OTHER: questionnaire administration

  • Ancillary studies
NO_INTERVENTION: Arm II (usual care)

Participants receive usual care.

Primary Outcome MeasuresMeasure DescriptionTime Frame
Effects of Family Caregiver Palliative Care Intervention (FCPCI) on caregiver burdenAnalysis of covariance (ANCOVA) will be used to test group differences. Caregiver burden subscales may be tested using multivariate ANCOVA (MANCOVA).Up to 6 months
Effects of FCPCI on caregiving skills preparednessANCOVA will be used to test group differences. Caregiver burden subscales may be tested using MANCOVA.Up to 6 months
Effects of FCPCI on Quality Of Life (QOL)ANCOVA will be used to test group differences. MANCOVA may be used to test group differences of QOL subscale scores.Up to 6 months
Effects of FCPCI on psychological distressANCOVA will be used to test group differences. MANCOVA may be used to test group differences of QOL subscale scores.Up to 6 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Caregiver's self-care behaviorQualitative analyses will be conducted on the narrative responses to the Self-Care Behaviors instrument. Self-care behaviors will be coded within each category. Results will be reviewed for consensus and validation, and any discrepancies will be resolved. Tables of coded themes with examples will be created.Up to 6 months
Caregivers' resource useThe qualitative analysis will be conducted on the narrative responses to the Resource Use instrument. Resources will be coded within each category. Results will be reviewed for consensus and validation, and any discrepancies will be resolved. Tables of categories and codes will be created.Up to 6 months
Identification of subgroups of family caregivers who benefit most from the FCPCI in relation to sociodemographic, health status, and patient characteristicsIn four separate hierarchical multiple linear regression analyses, the 3 month outcome measure (caregiver burden, skills preparedness, psychological distress, and total QOL) will be regressed first on baseline measures for the relevant outcomes, followed by demographic and caregiver health status variables, and then by patient characteristics and severity of illness, using dummy-coding as appropriate.3 months
Family caregivers' satisfaction with the FCPCIA descriptive analysis of the brief satisfaction survey item results for subjects in the experimental group will be conducted, summarizing number and percent for normal data or means and standard deviations for continuous data.6 months
Caregiver out-of-pocket costsA descriptive analysis of family caregivers' costs will be conducted.Up to 6 months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:
1

    Inclusion Criteria:

  • Primary family caregivers of cancer patients with gastrointestinal (colorectal, pancreatic, gastric), gynecologic, urinary or lung cancers who are entering the City of Hope for treatment or follow-up
  • Primary family caregivers of cancer patients who are diagnosed with stage II-IV disease
  • Primary family caregivers of cancer patients with > 6 months prognosis
  • Living within a 50 mile radius of the City of Hope

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • National Cancer Institute (NCI)
  • American Cancer Society (ACS) National Office

  • PRINCIPAL_INVESTIGATOR: Betty Ferrell, City of Hope Medical Center

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available